Targeting Multiple Cancer Types by Micellar Delivery of the Immunotherapeutic 15-deoxy-D12,14-Prostamide J2 Grant uri icon

abstract

  • The drug 15-deoxy, ?12,14-prostaglandin J2-ethanolamide (15dPMJ2) has been shown to selectively kill melanoma, nonmelanoma skin cancer, and colon cancer cells. However, the current method for drug deliver, that of direct injection into tumors, limits the scope of cancers treatable with 15dPMJ2. This project will develop a delivery system for the drug based on micelles - surfactant aggregates such as those formed by soaps and detergents - which will allow the drug to be administer by injection into the circulatory system. This approach will allow the drug to reach and preferentially accumulate in tumors throughout the body, thus minimizing possible side effects and extending the range of cancers treatable with 15dPMJ2.

date/time interval

  • July 2022 - January 2024